IN2015DN02912A - - Google Patents

Download PDF

Info

Publication number
IN2015DN02912A
IN2015DN02912A IN2912DEN2015A IN2015DN02912A IN 2015DN02912 A IN2015DN02912 A IN 2015DN02912A IN 2912DEN2015 A IN2912DEN2015 A IN 2912DEN2015A IN 2015DN02912 A IN2015DN02912 A IN 2015DN02912A
Authority
IN
India
Prior art keywords
pi3k
oxazolidin
phosphatidylinositol
kinase
inhibitors
Prior art date
Application number
Other languages
English (en)
Inventor
Robin Alec Fairhurst
Pascal Furet
Frank Stephan Kalthoff
Andreas Lerchner
Heinrich Rueeger
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2015DN02912A publication Critical patent/IN2015DN02912A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN2912DEN2015 2012-11-12 2013-11-11 IN2015DN02912A (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261725113P 2012-11-12 2012-11-12
PCT/IB2013/060052 WO2014072956A1 (en) 2012-11-12 2013-11-11 Oxazolidin-2-one-pyrimidine derivatives

Publications (1)

Publication Number Publication Date
IN2015DN02912A true IN2015DN02912A (da) 2015-09-11

Family

ID=49667527

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2912DEN2015 IN2015DN02912A (da) 2012-11-12 2013-11-11

Country Status (43)

Country Link
US (3) US9296733B2 (da)
EP (2) EP3199158B1 (da)
JP (1) JP6262245B2 (da)
KR (1) KR102153763B1 (da)
CN (1) CN104718204B (da)
AP (1) AP2015008347A0 (da)
AR (1) AR093408A1 (da)
AU (1) AU2013343022B2 (da)
BR (1) BR112015010136A2 (da)
CA (1) CA2890942C (da)
CL (1) CL2015001202A1 (da)
CO (1) CO7380758A2 (da)
CR (1) CR20150248A (da)
CU (1) CU24365B1 (da)
CY (1) CY1119391T1 (da)
DK (1) DK2922848T5 (da)
EA (2) EA027987B1 (da)
EC (1) ECSP15025093A (da)
ES (1) ES2641820T3 (da)
HK (1) HK1209108A1 (da)
HR (1) HRP20171425T1 (da)
HU (1) HUE034492T2 (da)
IL (1) IL238239A (da)
IN (1) IN2015DN02912A (da)
JO (1) JO3334B1 (da)
LT (1) LT2922848T (da)
MA (1) MA38076A1 (da)
MX (1) MX363436B (da)
MY (1) MY174239A (da)
NZ (1) NZ706591A (da)
PE (1) PE20151006A1 (da)
PH (1) PH12015501053A1 (da)
PL (1) PL2922848T3 (da)
PT (1) PT2922848T (da)
RS (1) RS56336B1 (da)
SG (1) SG11201503447QA (da)
SI (1) SI2922848T1 (da)
TN (1) TN2015000120A1 (da)
TW (1) TWI608005B (da)
UA (1) UA114001C2 (da)
UY (1) UY35128A (da)
WO (1) WO2014072956A1 (da)
ZA (1) ZA201502175B (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20141581A1 (es) 2011-09-27 2014-11-14 Novartis Ag 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
KR20150131224A (ko) 2013-03-14 2015-11-24 노파르티스 아게 돌연변이 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온
CA3037469C (en) 2015-09-24 2024-04-16 Drexel University Treatment of dermal disorders comprising a mtorc1 inhibitor
US10993947B2 (en) 2016-05-18 2021-05-04 Torqur Treatment of skin lesions
TW201929861A (zh) 2017-11-06 2019-08-01 瑞士商諾華公司 包含㗁唑啶-2-酮-嘧啶衍生物之調配物
MX2023002850A (es) 2020-09-10 2023-07-07 Precirix N V Fragmento de anticuerpo contra proteina activadora de fibroblastos (fap).
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB581334A (en) 1943-09-29 1946-10-09 Francis Henry Swinden Curd New pyrimidine compounds
JPS4921148B1 (da) 1970-12-28 1974-05-30
JPS4921149B1 (da) 1970-12-28 1974-05-30
AT340933B (de) 1973-08-20 1978-01-10 Thomae Gmbh Dr K Verfahren zur herstellung neuer pyrimidinderivate und ihrer saureadditionssalze
DE2341925A1 (de) 1973-08-20 1975-03-06 Thomae Gmbh Dr K Neue pyrimidinderivate und verfahren zu ihrer herstellung
US4994386A (en) 1987-07-13 1991-02-19 Pharmacia Diagnostics, Inc. Production of HBLV virus in the HSB-2 cell line
US4929726A (en) 1988-02-09 1990-05-29 Georgia State University Foundation, Inc. Novel diazines and their method of preparation
EP0330263A1 (en) 1988-02-25 1989-08-30 Merck & Co. Inc. Piperazinylalkylpyrimidines as hypoglycemic agents
GB9012311D0 (en) 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
US5358945A (en) 1990-07-03 1994-10-25 Mitsui Petrochemical Industries, Ltd. Pyrimidine compound and pharmaceutically acceptable salts thereof
JP3145410B2 (ja) 1995-04-13 2001-03-12 大鵬薬品工業株式会社 新規な４，６−ジアリールピリミジン誘導体及びその塩
JP3734907B2 (ja) 1996-12-19 2006-01-11 富士写真フイルム株式会社 現像処理方法
JP4276376B2 (ja) 1997-07-24 2009-06-10 全薬工業株式会社 複素環式化合物及びそれを有効成分とする抗腫瘍剤
JPH11158073A (ja) 1997-09-26 1999-06-15 Takeda Chem Ind Ltd アデノシンａ３拮抗剤
US6440965B1 (en) 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
US6150362A (en) 1997-12-12 2000-11-21 Henkin; Jack Triazine angiogenesis inhibitors
PT930302E (pt) 1998-01-16 2003-07-31 Hoffmann La Roche Derivados de benzo-sulfona
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
WO1999065897A1 (en) 1998-06-19 1999-12-23 Chiron Corporation Inhibitors of glycogen synthase kinase 3
EP1144390A2 (en) 1999-01-22 2001-10-17 Amgen Inc., Kinase inhibitors
US6495558B1 (en) 1999-01-22 2002-12-17 Amgen Inc. Kinase inhibitors
ATE253915T1 (de) 1999-06-30 2003-11-15 Merck & Co Inc Src-kinase hemmende verbindungen
EP1206260A4 (en) 1999-06-30 2002-10-30 Merck & Co Inc SRC-KINASE INHIBITING COMPOUNDS
WO2001000214A1 (en) 1999-06-30 2001-01-04 Merck & Co., Inc. Src kinase inhibitor compounds
JP2003505384A (ja) 1999-07-15 2003-02-12 ファーマコピーア，インコーポレーティッド ブラジキニンｂ１受容体アンタゴニスト
JP2001089452A (ja) 1999-09-22 2001-04-03 Sankyo Co Ltd ピリミジン誘導体
WO2001060816A1 (en) 2000-02-17 2001-08-23 Amgen Inc. Kinase inhibitors
GB2361236B (en) 2000-03-29 2002-04-24 Cyclacel Ltd Pyrimidines useful against proliferative disorders
AU5261001A (en) 2000-04-27 2001-11-12 Imperial Cancer Research Technology Ltd Condensed heteroaryl derivatives
US7220736B2 (en) 2000-04-28 2007-05-22 Tanabe Seiyaku Co., Ltd. Pyrimidine compounds
JP2004501913A (ja) 2000-06-23 2004-01-22 ブリストル−マイヤーズ　スクイブ　ファーマ　カンパニー ヘテロアリール−フェニル置換Ｘａ因子阻害剤
AU2001295026B2 (en) 2000-09-06 2008-04-03 Novartis Vaccines And Diagnostics, Inc. Inhibitors of glycogen synthase kinase 3
WO2002022605A1 (en) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
SE0004053D0 (sv) 2000-11-06 2000-11-06 Astrazeneca Ab N-type calcium channel antagonists for the treatment of pain
US6989385B2 (en) 2000-12-21 2006-01-24 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2002062766A2 (en) 2001-02-07 2002-08-15 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
US20030130264A1 (en) 2001-02-16 2003-07-10 Tularik Inc. Methods of using pyrimidine-based antiviral agents
EP1395561A1 (en) 2001-05-25 2004-03-10 Boehringer Ingelheim Pharmaceuticals Inc. Carbamate and oxamide compounds as inhibitors of cytokine production
HUP0402352A2 (hu) 2001-06-19 2005-02-28 Bristol-Myers Squibb Co. Foszfodiészteráz (PDE) 7 inhibitorként alkalmazható pirimidinszármazékok és ezeket tartalmazó gyógyszerkészítmények
US6603000B2 (en) 2001-07-11 2003-08-05 Boehringer Ingelheim Pharmaceuticals, Inc. Synthesis for heteroarylamine compounds
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US7091343B2 (en) 2002-03-15 2006-08-15 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
AU2003225800A1 (en) 2002-03-15 2003-09-29 Hayley Binch Azolylaminoazine as inhibitors of protein kinases
ES2289279T3 (es) 2002-03-15 2008-02-01 Vertex Pharmaceuticals Incorporated Composiciones utiles como inhibidores de proteinquinasas.
US20040009981A1 (en) 2002-03-15 2004-01-15 David Bebbington Compositions useful as inhibitors of protein kinases
AU2003245669A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain aromatic monocycles as kinase modulators
WO2004029204A2 (en) 2002-09-27 2004-04-08 Merck & Co., Inc. Substituted pyrimidines
US20040171073A1 (en) 2002-10-08 2004-09-02 Massachusetts Institute Of Technology Compounds for modulation of cholesterol transport
US7223870B2 (en) 2002-11-01 2007-05-29 Pfizer Inc. Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction
KR101052482B1 (ko) 2002-11-21 2011-07-28 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 포스포티딜이노시톨(ｐｉ) 3-키나제 억제제인 2,4,6-삼치환피리미딘 및 암의 치료에서 이들의 사용
EP1608622A4 (en) 2003-03-24 2009-04-01 Merck & Co Inc BIARYLSUBSTITUTED 6-LOW HETEROCYCLES AS SODIUM CHANNEL BLOCKERS
US20050014753A1 (en) 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
JP4895806B2 (ja) 2003-04-09 2012-03-14 エクセリクシス， インク． Ｔｉｅ−２モジュレータと使用方法
AU2004259712A1 (en) 2003-07-15 2005-02-03 Neurogen Corporation Substituted pyrimidin-4-ylamine analogues
EP1644358A2 (en) 2003-07-16 2006-04-12 Neurogen Corporation Biaryl piperazinyl-pyridine analogues
AR045944A1 (es) 2003-09-24 2005-11-16 Novartis Ag Derivados de isoquinolina 1.4-disustituidas
ATE485824T1 (de) 2004-04-13 2010-11-15 Icagen Inc Polycyclische pyrimidine als kaliumionenkanal- modulatoren
GB0415364D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
GB0415365D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
MY145822A (en) 2004-08-13 2012-04-30 Neurogen Corp Substituted biaryl piperazinyl-pyridine analogues
WO2006060318A2 (en) * 2004-11-30 2006-06-08 Amgen Inc. Quinolines and quinazoline analogs and their use as medicaments for treating cancer
JP2008523156A (ja) 2004-12-13 2008-07-03 ニューロジェン・コーポレーション 置換ビアリール類縁体
AU2005317176A1 (en) 2004-12-13 2006-06-22 Neurogen Corporation Piperazinyl-pyridine analogues
KR101478933B1 (ko) 2004-12-28 2015-01-02 키넥스 파마슈티컬즈, 엘엘씨 세포 증식 질환의 치료를 위한 조성물 및 방법
CN101107245A (zh) 2005-01-19 2008-01-16 神经能质公司 经杂芳基取代的哌嗪-吡啶类似物
AU2006217742A1 (en) 2005-02-25 2006-08-31 Kudos Pharmaceuticals Limited Hydrazinomethyl, HYDR zonomethyl and 5-membered heterocylic compounds which act as MTOR inhibitors and their use as anti cancer agents
AU2006236387A1 (en) 2005-04-18 2006-10-26 Neurogen Corporation Subtituted heteroaryl CB1 antagonists
GB2431156A (en) 2005-10-11 2007-04-18 Piramed Ltd 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase
CA2635997A1 (en) 2006-01-11 2007-07-19 Astrazeneca Ab Morpholino pyrimidine derivatives and their use in therapy
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
WO2007120897A2 (en) * 2006-04-13 2007-10-25 The Trustees Of Columbia University In The City Of New York Compositions and intraluminal devices for inhibiting vascular stenosis
CL2007003847A1 (es) 2006-12-28 2008-04-18 Basf Ag Compuestos derivados de pirimidinas 2,4,5 tri-sustituidas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento del cancer.
ATE551334T1 (de) 2007-02-06 2012-04-15 Novartis Ag Pi3-kinase-hemmer und verfahren zu ihrer verwendung
US7957951B2 (en) 2007-03-16 2011-06-07 Robert Bosch Gmbh Address translation system for use in a simulation environment
KR20100031639A (ko) 2007-07-09 2010-03-23 아스트라제네카 아베 증식성 질환의 치료용 삼중 치환된 피리미딘 유도체
WO2009066084A1 (en) 2007-11-21 2009-05-28 F. Hoffmann-La Roche Ag 2 -morpholinopyrimidines and their use as pi3 kinase inhibitors
WO2009109605A1 (en) 2008-03-05 2009-09-11 Novartis Ag Use of pyrimidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members
WO2009118324A1 (en) 2008-03-26 2009-10-01 Novartis Ag 5imidazoquinolines and pyrimidine derivatives as potent modulators of vegf-driven angiogenic processes
EP2276750A2 (en) 2008-03-27 2011-01-26 Auckland Uniservices Limited Substituted pyrimidines and triazines and their use in cancer therapy
TW200948362A (en) 2008-04-09 2009-12-01 Mitsubishi Tanabe Pharma Corp New compounds and their uses
GB0815369D0 (en) 2008-08-22 2008-10-01 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
RU2538683C2 (ru) 2008-10-31 2015-01-10 Новартис Аг КОМБИНАЦИЯ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТОЛ-3-КИНАЗЫ (Р13К) И ИНГИБИТОРА mTOR
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
WO2010068863A2 (en) 2008-12-12 2010-06-17 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
JP5747440B2 (ja) 2009-02-06 2015-07-15 住友化学株式会社 ヒドラジド化合物及びその有害生物防除用途
BRPI1008661B8 (pt) 2009-02-06 2021-05-25 Nippon Shinyaku Co Ltd compostos derivados de aminopirazina, seu uso e composição farmacêutica
EP2406389B1 (en) 2009-03-13 2019-05-08 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
WO2010120994A2 (en) 2009-04-17 2010-10-21 Wyeth Llc Ureidoaryl-and carbamoylaryl-morpholino- pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis
CA2760911A1 (en) 2009-05-19 2010-11-25 George E. Davis Compounds and methods for controlling fungi
EP2532659A1 (en) 2009-07-07 2012-12-12 Pathway Therapeutics, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
US8609676B2 (en) 2009-08-04 2013-12-17 Merck Sharp & Dohme, Corp. 4, 5, 6-trisubstituted pyrimidine derivatives as factor IXa inhibitors
AR077999A1 (es) 2009-09-02 2011-10-05 Vifor Int Ag Antagonistas de pirimidin y triazin-hepcidina
CN102625708A (zh) 2009-09-09 2012-08-01 阿维拉制药公司 Pi3激酶抑制剂及其用途
ES2642109T3 (es) 2009-12-09 2017-11-15 Agios Pharmaceuticals, Inc. Compuestos terapéuticamente activos para su uso en el tratamiento de cáncer caracterizados por tener una mutación de IDH
GB201004200D0 (en) 2010-03-15 2010-04-28 Univ Basel Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
WO2011133920A1 (en) 2010-04-23 2011-10-27 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
US20130109643A1 (en) 2010-05-10 2013-05-02 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
EP2593425B1 (en) 2010-07-16 2018-10-17 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their method of use
EP2621908A2 (en) 2010-10-01 2013-08-07 Novartis AG Manufacturing process for pyrimidine derivatives
LT2629776T (lt) 2010-10-18 2017-11-10 Cerenis Therapeutics Holding Sa Junginiai, kompozicijos ir būdai, tinkami cholesterolio mobilizavimui
GB201106829D0 (en) 2011-04-21 2011-06-01 Proximagen Ltd Heterocyclic compounds
JP2014505107A (ja) 2011-02-11 2014-02-27 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 過誤腫性腫瘍細胞を阻害する方法
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
KR20140059786A (ko) 2011-09-01 2014-05-16 노파르티스 아게 골암의 치료에 사용하기 위한 또는 골 내로의 원발성 암 세포의 전이성 파종을 예방하기 위한 pi3k 억제제
PE20141581A1 (es) 2011-09-27 2014-11-14 Novartis Ag 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante
US9365562B2 (en) 2011-10-06 2016-06-14 Merck Sharp & Dohme Corp. 1,3 substituted azetidine PDE10 inhibitors
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
RU2630975C2 (ru) * 2012-05-16 2017-09-15 Новартис Аг Режим дозирования pi-3 киназы
BR112014030099A2 (pt) 2012-06-06 2017-06-27 Novartis Ag combinação de um inibidor 17-alfa-hidroxilase(c17,20-liase) e um inibidor pi-3 k específico para tratamento de uma doença de tumor
JP2015529194A (ja) 2012-08-16 2015-10-05 ノバルティス アーゲー ＰＩ３Ｋインヒビターとｃ−Ｍｅｔインヒビターの組み合わせ
PL2912030T3 (pl) 2012-10-23 2017-02-28 Novartis Ag Ulepszony sposób wytwarzania 5-(2,6-di-4-morfolinylo-4-pirymidynylo)-4- trifluorometylopirydyno-2-aminy
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
ES2651132T3 (es) 2013-03-14 2018-01-24 Novartis Ag 3-Pirimidin-4-il-oxazolidin-2-onas como inhibidores de IDH mutante
KR20150131224A (ko) 2013-03-14 2015-11-24 노파르티스 아게 돌연변이 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온
CN103483345B (zh) 2013-09-25 2016-07-06 中山大学 Pi3k激酶抑制剂、包含其的药物组合物及其应用
CN103694218B (zh) 2013-12-05 2016-04-27 中山大学 嘧啶化合物、pi3k抑制剂、包含pi3k抑制剂的药物组合物及应用

Also Published As

Publication number Publication date
MX2015005914A (es) 2015-09-08
UY35128A (es) 2014-06-30
AR093408A1 (es) 2015-06-03
TW201427974A (zh) 2014-07-16
TN2015000120A1 (en) 2016-06-29
EP2922848A1 (en) 2015-09-30
LT2922848T (lt) 2017-09-25
SI2922848T1 (sl) 2017-10-30
ECSP15025093A (es) 2019-03-29
HK1209108A1 (en) 2016-03-24
US20140135330A1 (en) 2014-05-15
EA027987B1 (ru) 2017-09-29
PH12015501053B1 (en) 2015-07-27
SG11201503447QA (en) 2015-05-28
JP6262245B2 (ja) 2018-01-17
US20160168145A1 (en) 2016-06-16
TWI608005B (zh) 2017-12-11
ES2641820T3 (es) 2017-11-14
BR112015010136A2 (pt) 2017-07-11
EA201790289A1 (ru) 2017-06-30
KR20150082295A (ko) 2015-07-15
ZA201502175B (en) 2018-05-30
KR102153763B1 (ko) 2020-09-09
UA114001C2 (xx) 2017-04-10
CA2890942C (en) 2021-01-12
MX363436B (es) 2019-03-22
US9296733B2 (en) 2016-03-29
US10202371B2 (en) 2019-02-12
DK2922848T3 (da) 2017-10-09
PT2922848T (pt) 2017-10-05
CL2015001202A1 (es) 2015-07-03
US20190382399A1 (en) 2019-12-19
EP3199158A1 (en) 2017-08-02
CN104718204B (zh) 2017-11-28
AU2013343022A1 (en) 2015-04-23
AP2015008347A0 (en) 2015-04-30
CO7380758A2 (es) 2015-09-10
CU20150050A7 (es) 2015-11-27
EA201590929A1 (ru) 2015-08-31
CU24365B1 (es) 2018-10-04
HUE034492T2 (en) 2018-02-28
JO3334B1 (ar) 2019-03-13
EA029714B1 (ru) 2018-05-31
RS56336B1 (sr) 2017-12-29
PE20151006A1 (es) 2015-07-04
NZ706591A (en) 2016-03-31
MY174239A (en) 2020-04-01
MA38076A1 (fr) 2018-02-28
CA2890942A1 (en) 2014-05-15
DK2922848T5 (da) 2017-10-30
AU2013343022B2 (en) 2015-08-20
PH12015501053A1 (en) 2015-07-27
PL2922848T3 (pl) 2017-12-29
EP3199158B1 (en) 2019-04-17
CY1119391T1 (el) 2018-02-14
CR20150248A (es) 2015-07-01
CN104718204A (zh) 2015-06-17
EP2922848B1 (en) 2017-06-28
WO2014072956A1 (en) 2014-05-15
JP2015536974A (ja) 2015-12-24
IL238239A (en) 2017-05-29
HRP20171425T1 (hr) 2017-11-17

Similar Documents

Publication Publication Date Title
PH12014501900A1 (en) Oxazolidin-2-one compounds and uses thereof as pi3ks inhibitors
AU2018236800B2 (en) DNA-PK inhibitors
PH12015501053B1 (en) Oxazolidin-2-one-pyrimidine derivatives
PH12016501160A1 (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
IN2014KN02601A (da)
EA024842B9 (ru) Соединения в качестве модуляторов протеинкиназы pi3k
UA117830C2 (uk) Похідні біпіразолу як інгібітори jak
MD20150071A2 (ro) Compuşi azabenzimidazolici ca inhibitori ai PDE4 izoenzimelor pentru tratamentul tulburărilor SNC şi altor afecţiuni
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
MX2017013137A (es) Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas.
MX2015000179A (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
AU2012312301A8 (en) Compounds useful as inhibitors of choline kinase
TN2014000340A1 (en) Oxazolidin- 2 -one compounds and uses thereof as pi3ks inhibitors
MX2015012393A (es) Derivados oxindol con un sustituyente oxetano y uso de los mismos para tratar enfermedades relacionadas con la vasopresina.